Skin Cancer
265
51
71
135
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
48 trials with published results (18%)
Research Maturity
135 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.5%
20 terminated out of 265 trials
87.1%
+0.5% vs benchmark
5%
14 trials in Phase 3/4
36%
48 of 135 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 135 completed trials
Clinical Trials (265)
E-MOHS Trial of TENS and Vibration During Local Anesthesia
Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision
Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery
Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program
Mobile Sun Health Intervention EnabLing Daily Protection
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Lower Extremity Graft Study (LEGS): A Multicentre Randomised Controlled Trial of Negative Pressure Wound Therapy Versus Conventional Dressings for Split-thickness Skin Grafts After Lower Leg Skin Tumour Excision
Cryoablation+Ipilimumab+Nivolumab in Melanoma
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers Phase I
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Rural Adult and Youth Sun Protection Study
A Model for Genetic Susceptibility: Melanoma
Adaptive Symptom Self-Management Immunotherapy Study
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
Undergraduate Skin Cancer Prevention Trial
The Florida ASCENT Study
DNA Repair Activity in the Skin of Day and Night Shift Workers
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients